文献速递肿瘤 PET/CT放射性药物与辐射防护

碳酸酐酶IX靶向肽[68Ga]Ga-DPI-4452在透明细胞肾细胞癌患者中的首次人体安全性、显像与剂量学研究

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.
PubMed 文献 · J Nucl Med · 2024-02-22

本研究在3例透明细胞肾细胞癌患者中评估了[68Ga]Ga-DPI-4452的显像特征、剂量学、药代动力学和安全性。给药后行系列全身PET/CT显像,肿瘤在所有时间点(15分钟至4小时)均可见摄取,36个病灶给药后1小时SUVmax范围为6.8至211.6(均值64.6,标准差54.8)。肾脏、肝脏和骨髓活性低,血液和尿液中快速清除,未观察到临床显著毒性。

要点

  • 3例透明细胞肾细胞癌患者中,[68Ga]Ga-DPI-4452在所有时间点(15分钟至4小时)均显示肿瘤摄取。
  • 36个病灶给药后1小时SUVmax范围为6.8至211.6(均值64.6,标准差54.8)。
  • 肾脏、肝脏和骨髓活性低,血液和尿液中快速清除,未观察到临床显著毒性。

核心结论

  • [68Ga]Ga-DPI-4452在透明细胞肾细胞癌患者中显示优异的肿瘤摄取,肿瘤与本底比值非常高,无显著不良事件,提示潜在的诊断和患者选择应用。

研究设计与样本

  • 首次人体研究,在3例透明细胞肾细胞癌患者中评估[68Ga]Ga-DPI-4452的显像特征、剂量学、药代动力学和安全性。
  • 给药后行系列全身PET/CT显像,并采集血液和尿液样本,注射后监测安全性7天。

主要发现

  • 肿瘤在所有时间点(15分钟至4小时)均可见摄取。
  • 36个病灶给药后1小时SUVmax范围为6.8至211.6(均值64.6,标准差54.8)。
  • 肾脏、肝脏和骨髓显示低活性。
  • [68Ga]Ga-DPI-4452从血液和尿液中快速清除。
  • 未观察到临床显著毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[68Ga]Ga-DPI-4452, a first-in-class carbonic anhydrase IX-binding radiolabeled peptide, is the imaging agent of a theranostic pair with [177Lu]Lu-DPI-4452, developed for selecting and treating patients with carbonic anhydrase IX-expressing tumors. Here, [68Ga]Ga-DPI-4452 imaging characteristics, dosimetry, pharmacokinetics, and safety were assessed in 3 patients with clear cell renal cell carcinoma. Methods: After [68Ga]Ga-DPI-4452 administration, patients underwent serial full-body PET/CT imaging. Blood and urine were sampled. Safety was monitored for 7 d after injection. Results: Tumor uptake was observed at all time points (15 min to 4 h). Across 36 lesions, the SUVmax at 1 h after administration ranged from 6.8 to 211.6 (mean, 64.6 [SD, 54.8]). The kidneys, liver, and bone marrow demonstrated low activity. [68Ga]Ga-DPI-4452 was rapidly eliminated from blood and urine. No clinically significant toxicity was observed. Conclusion: [68Ga]Ga-DPI-4452 showed exceptional tumor uptake in patients with clear cell renal cell carcinoma, with very high tumor-to-background ratios and no significant adverse events, suggesting potential diagnostic and patient selection applications.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hofman MS, Tran B, Feldman DR, et al. First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma. J Nucl Med. 2024. PMID: 38388517. doi:10.2967/jnumed.123.267175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。